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Objective: To identify factors associated with diagnosis and health-related quality
of life (HRQL) impairment in chronic obstructive pulmonary disease (COPD) patients
from a population-based epidemiological study.
Design and participants: This was an epidemiologic, multicenter, population-based
study. Three hundred and sixty-three individuals diagnosed with COPD from a
randomly general population sample of 4035 individuals aged 40–69 were included in
the analyses.
Interventions: Forced spirometry was performed on eligible subjects, and the
European Commission for Steel and Coal (ECSC) and the St. George’s Respiratory
Questionnaires (SGRQ) were completed. Logistic regression models were constructed
to identify variables associated with the previous diagnosis of COPD and with COPD inElsevier Ltd. All rights reserved.
n unrestricted grant from Boehringer Ingelheim Spain, S.A.
4 9 3227 5549.
s (M. Miravitlles).
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M. Miravitlles et al.986never smokers. A multiple linear regression model attempted to identify variables
influencing HRQL impairment.
Results: Only 79 (21.7%) COPD patients had been previously diagnosed. Disease
severity based on FEV1, worse SGRQ score, previous respiratory disease, as well as
the presence of wheezing were significantly associated with previous diagnosis.
Being a woman, older than 55, with previous respiratory disease and without
expectoration or wheezing characterized COPD in never smokers. A worse HRQL was
associated with chronic symptoms, especially dyspnea; and with older age, cardiac
comorbidity and impairment in lung function.
Conclusions: Diagnosis of COPD in the community is more likely in patients with
worse lung function and HRQL, and wheezing is the symptom most strongly
associated with a diagnosis of COPD. Women older than 55, with previous respiratory
diseases, without respiratory symptoms and mild airflow obstruction constitute the
majority of individuals with COPD who have never smoked. Chronic respiratory
symptoms are strongly associated with impairment in HRQL.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
frequent cause of morbidity and mortality in
developed countries. Despite campaigns against
tobacco smoking, the prevalence of this disease
and mortality rates due to COPD continue to
increase. From 1979 to 1993, the age-adjusted
mortality rate in the United States increased to
47.3%1 and is still on the rise.
COPD represents a large economic burden to
society. The mean annual direct medical cost of a
patient with COPD in Spain has been quantified in
$18762 and up to $10,812 for severe patients in the
US.3 An economic study demonstrated that the best
strategy to reduce costs in COPD is the early
diagnosis of the disease, with adequate manage-
ment in early stages,4 this is explained by the fact
that the costs of a severe case are as much as seven
times higher than the costs of a mild case.5
However, several studies have demonstrated that
a large proportion of patients with COPD in the
community remain undiagnosed6–8 and this lack of
diagnosis prevents patients from receiving anti-
smoking counselling and adequate treatment and
follow-up.
The IBERPOC is a population-based epidemiolo-
gical multicenter study in Spain aimed to establish
the prevalence of COPD in the age group of 40–69
years of age.6 The results of the study showed a
prevalence of 9.1%. Increasing tobacco consump-
tion, higher age, male sex, urban habitat, a higher
educational level and existence of chronic bron-
chitis (CB) or other thoracic diseases were sig-
nificantly associated with COPD compared with
individuals without the disease.6 One of the most
relevant findings of the study was that only 21.7% of
the cases of COPD had been previously diagnosed.In the present study, we analyze the demographic
and clinical characteristics of the group of COPD
patients identified in the IBERPOC study. We
identified the factors associated with previous
diagnosis of COPD and with health-related quality
of life (HRQL) impairment in this population-based
sample of individuals with COPD.Method
Design
IBERPOC was a cross-sectional study of a non-
institutionalized general population of 40–69 years
of age from seven areas of different sizes and urban
characteristics in Spain. The main objective of the
IBERPOC study was to determine the prevalence of
COPD in seven areas of Spain. Details on the
IBERPOC survey methods have been described
previously.6,9 Briefly, a random sample proportion-
ally stratified by gender and age (40–49, 50–59,
60–69) was drawn from the local census register at
each site. The response rate was 69% out of a total
sample of 5827 eligible individuals (932 refused the
interview and 860 could not be contacted). A total
of 4035 participants were clinically assessed by a
pneumologist.
The European Commission for Steel and Coal
(ECSC) questionnaire translated into Spanish was
used for assessment of respiratory symptoms and
smoking history.10 A subject was considered to be a
smoker if he/she consumed at least one cigarette,
pipe or cigar a day, and an ex-smoker if he/she had
completely stopped consumption of any type of
tobacco for at least the previous 6 months and had
a life-long cumulative consumption of at least 1
ARTICLE IN PRESS
Characteristics of a population of COPD patients identified from a population-based study 987pack-year. Information obtained on social class was
based on an adaptation of the British Registrar
General’s classification, in which classes IV and
above represent the lowest classes and I–II the
wealthiest.11
The Spanish versions of the St. George’s Respira-
tory Questionnaire (SGRQ)12,13 and the SF-12 Health
Survey were completed by the patient.14,15 The
SGRQ is a supervised, self-administered measure
specifically designed for evaluation of HRQL in
patients with airway disease. Scores vary from 0 (no
disability or perfect health status) to 100 (max-
imum disability or worst health status). A change of
four units in the SGRQ score is considered clinically
significant.16 The SGRQ is a valid measure of
health status and well-being in chronic airflow
limitation and correlates with changes following
therapy. The SGRQ was completed under the
supervision of the local investigator in each study
area and according to guidelines in the manual. The
SF-12 Health Survey is a reduced version of the SF-
36 Survey and contains 12 items.14 This short
version accounts for more than 90% of the variance
of Physical and Mental Component Summary scores
constructed from the eight SF-36 scales. Summary
scores were standardized to have a mean of 50 and
standard deviation of 10 in the Spanish adult
general population used as the reference popula-
tion.15 In contrast to the SGRQ scoring system,
higher scores in the SF-12 Survey indicate im-
proved health status; with values 450 indicating
improved health status compared to the reference
population.
Since this was an epidemiological study aimed to
investigate the prevalence of COPD, other comor-
bidities were not extensively studied. However, we
collected information on other chronic respiratory
diseases: past tuberculosis, bronchiectasis, chronic
asthma, silicosis; and cardiac comorbidity.Spirometry
The subjects were requested to undergo a spiro-
metry according to the American Thoracic Society
guidelines,17 with the same type of portable
spirometer (DATOSPIR-200. Sibel S.A. Barcelona)
used in all seven areas. Subjects whose FEV1/FVC
value was o88% predicted in men or o89% in
women underwent a bronchodilator test (BDT) with
two inhalations of salbutamol, using an inhalation
chamber. The BDT was performed by inhalation of
200 mg of salbutamol through an inhalation chamber
and was considered positive if the difference
between FEV1 or FVC before and 15min after thetest was above 200ml and its relative increase was
over 12%.Diagnostic criteria of COPD
For the diagnosis of COPD, subjects were required
to have no previous diagnosis of asthma (reply in
the ECSC questionnaire) and to present the func-
tional obstruction criteria of the European Respira-
tory Society (ERS) on spirometry;18 i.e. a FEV1/FVC
ratio in percentage predicted lower than 88% in
men or 89% in women. In order to avoid the
inclusion of patients with reversible airway ob-
struction due to asthma, diagnosis of COPD was
reserved for subjects with negative BDT or, in the
case of a positive BDT, values after the challenge
still had to fulfil the criteria for bronchial obstruc-
tion. In 15 cases in which BDT had not been
performed, an absolute FEV1/FVC value lower than
80% and FEV1o70% predicted were required for the
diagnosis of COPD, so that possible reversible
obstructions which could pass unnoticed were
reasonably avoided. ERS criteria were also followed
for staging COPD severity into mild (FEV1470%),
moderate (FEV1 between 50% and 70%) and severe
(FEV1o50%).18 To be consistent with the results
published from the same cohort of patients, the
definition of COPD and the cut-offs for the degrees
of severity have been respected as originally
described in the protocol. The ERS criteria were
chosen because the GOLD criteria were not avail-
able at that time.
Among individuals identified as COPD cases,
those who answered affirmatively to the question:
‘‘Has a doctor ever told you that you had COPD, CB
or emphysema?’’ constituted the previously diag-
nosed group.Statistical analysis
Differences in socio-demographic, COPD character-
istics and HRQL according to previous diagnosis of
COPD and smoking habits were tested by using the
unpaired t-test or Chi-square-test, depending on
the nature of the variables. To identify which
variables were independently associated with pre-
vious diagnosis and being a never smoker, the
adjusted ORs and 95% confidence intervals were
calculated by constructing logistic regression mod-
els. Finally, to investigate the variables associated
with impairment in HRQL, a lineal regression model
was computed with the total SGRQ score as a
dependent variable. Analysis of data was per-
formed using the Statistical Package for Social
Sciences version10.
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Variables associated with previous diagnosis
of COPD
Of the 363 COPD patients, only 79 (21.7%) had
been previously diagnosed with COPD, CB or
emphysema. The demographic and clinical char-
acteristics of patients according to this previous
diagnosis are presented in Tables 1 and 2. Com-
pared with undetected cases, patients with a
previous diagnosis of COPD were older, with more
comorbidity, particularly other respiratory dis-
eases, more frequently men and former smokers,
and presented more respiratory symptoms, a
poorer quality of life, and more severe impair-
ment in lung function. No significant differences
were observed in social class or schooling bet-
ween both groups. On multivariate analysis, age
between 55 and 64 years, former smoker, an
FEV1o50% predicted, the presence of wheezing,
other respiratory disease, and more severe impair-
ment in the total SGRQ score remained signi-Table 1 Characteristics of the sample of COPD patients
All patients
Age, mean (SD) 57.9 (8.4)
Sex (male), n (%) 283 (78.0)
Lung function, mean (SD)
FVC (ml) 3337.0 (923.6)
FVC (%) 80.3 (18.4)
FEV1 (ml) 1974.1 (628.7)
FEV1 (%) 64.1 (17.2)
FEV1/FVC (ml) 67.1 (63.5)
Comorbidities
Cardiac comorbidity 34 (9.4%)
Other respiratory diseases 83 (22.9%)
Comorbidity
No 218 (60.1%)
Yes 145 (39.9%)
SGRQ scores, mean (SD)
Symptoms 20.7 (17.8)
Impact 24.6 (24.1)
Activity 12.3 (15.7)
Total 17.7 (16.8)
SF-12, mean (SD)
Physical 48.4 (7.7)
Emotional 52.2 (9.7)
*P-value: unpaired t-test or w2; depending on the nature of the vficantly associated with the previous diagnosis of
COPD.
COPD in never smokers
Eighty-four (23.1%) of the COPD patients were
never smokers. The characteristics of never smo-
kers compared with current and former smokers are
presented in Table 3. Non-smokers with COPD were
more frequently women, had a milder impairment
in lung function and health status and presented
fewer respiratory symptoms compared with smo-
kers or former smokers with COPD. In contrast,
COPD in never smokers was more frequently
associated with other respiratory diseases. No
differences in social class or schooling were found
among the different groups.
The logistic regression model showed that being
a male (OR ¼ 41.2; 95% CI ¼ 16.0–106.1), chronic
expectoration (OR ¼ 7.2; 95% CI ¼ 1.3–40.5) and
wheezing (OR ¼ 2.2; 95% CI ¼ 1.0–5.1) were sig-
nificantly associated with smoking-related COPD
(Table 3)..
Previous diagnostic
No (n ¼ 284) Yes (n ¼ 79) P-value*
57.0 (8.7) 61.1 (6.5) o0.001
211 (74.3) 72 (91.1) 0.001
3447.9 (886.5) 2938.4 (949.6) o0.001
83.5 (17.0) 68.6 (18.6) o0.001
2082.0 (597.3) 1586.1 (587.7) o0.001
67.9 (15.6) 50.1 (15.5) o0.001
69.0 (64.2) 60.3 (60.6) 0.283
22 (7.7%) 12 (15.2%) 0.104
54 (19.0%) 29 (36.7%) 0.004
181 (63.7%) 37 (46.8%) 0.007
103 (36.3%) 42 (53.2%)
17.3 (15.3) 32.3 (20.9) o0.001
19.5 (21.1) 42.4 (25.4) o0.001
8.5 (11.5) 25.4 (20.7) o0.001
13.6 (13.1) 31.9 (20.2) o0.001
49.8 (6.6) 43.6 (9.5) o0.001
52.3 (9.5) 51.6 (10.6) 0.564
ariables.
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Table 2 Association between characteristics of COPD patients and previous diagnosis of COPD.
Previous diagnosis Logistic regression model
No (n ¼ 284) Yes (n ¼ 79) P-value* Adjusted OR CI 95%
Age
o55 years 117 (41.2) 13 (16.5) o0.001 — —
55–64 years 94 (33.1) 39 (49.4) 1.9 0.8, 4.9
65 or older 73 (25.7) 27 (34.2) 0.8 0.3, 2.4
Sex
Female 73 (25.7) 7 (8.9) 0.001 — —
Male 211 (74.3) 72 (91.1) 1.3 0.3, 6.2
Tobacco
Smokers 125 (44.0) 28 (35.4) o0.001 — —
Former smokers 83 (29.2) 43 (54.4) 2 0.9, 4.4
Never smokers 76 (26.8) 8 (10.1) 0.7 0.2, 3.0
Severity of COPD
Very mild (FEV1, %469) 132 (46.5) 7 (8.9) o0.001 — —
Mild (FEV1, % 50–69) 115 (40.5) 32 (40.5) 2.7 1.0, 7.4
Moderate or severe (FEV1, % o50) 37 (13.0) 40 (50.6) 6.7 2.1, 21.1
Cardiac comorbidity
No 260 (91.5%) 67 (84.4%) 0.104 — —
Yes 22 (7.7%) 12 (15.2%) 0.9 0.3, 2.6
Other respiratory diseases
No 225 (79.2%) 49 (62.0%) 0.004 — —
Yes 54 (19.0%) 29 (36.7%) 3.7 1.7, 8.2
Cough
No 201 (70.8) 43 (54.4) 0.006 — —
Yes 83 (29.2) 36 (45.6) 0.9 0.3, 2.3
Chronic expectoration
No 224 (78.9) 44 (55.7) o0.001 — —
Yes 60 (21.1) 35 (44.3) 1.1 0.4, 3.0
Wheezing
No 130 (45.8) 8 (10.1) o0.001 — —
Yes 154 (54.2) 71 (89.9) 3.6 1.4, 9.4
Dyspnea
No 248 (87.3) 49 (62.0) o0.001 — —
Yes 36 (12.7) 30 (38.0) 1.3 0.5, 3.0
Social class
Class I, II 21 (8.2) 6 (8.3) 0.123 — —
Class III 81 (31.6) 14 (19.4) 0.7 0.1, 3.1
Class IV-a, IV-b and V 154 (60.2) 52 (72.2) 0.9 0.2, 3.9
Total SGRQ score, mean (SD)
o7 113 (41.2) 5 (6.3) o0.001 — —
7–22 96 (35.0) 22 (27.8) 3.6 1.1, 12.4
422 65 (23.7) 52 (65.8) 8.1 2.2, 29.2
Values expressed as n (%), unless otherwise specified.
*P-value: unpaired t-test or w2 (Chi-squared), depending on the nature of the variables.
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Table 3 Association between characteristics of COPD patients and smoking habits.
Smoking habits Logistic regression model*
Smokers
(n ¼ 153)
Former
smokers
(n ¼ 126)
Never
(n ¼ 84)
P-value* Adjusted OR CI 95%
Age
o55 years 66 (43.1) 35 (27.8) 29 (34.5) 0.013 — —
55–64 years 58 (37.9) 45 (35.7) 30 (35.7) 0.3 0.1, 0.9
65 or older 29 (19.0) 46 (36.5) 25 (29.8) 0.3 0.1, 0.9
Sex (male)
Female 16 (10.5) 4 (3.2) 60 (71.4) o0.001 — —
Male 137 (89.5) 122 (96.8) 24 (28.6) 1.5 0.4, 5.4
Severity of COPD
Very mild
(%FEV1469)
49 (32.0) 35 (27.8) 55 (65.5) o0.001 — —
Mild (%FEV1:
50–69)
73 (47.7) 54 (42.9) 20 (23.8) 39.3 15.3, 101.1
Moderate or
severe
(%FEV1o50)
31 (20.3) 37 (29.4) 9 (10.7)
Other respiratory diseases
No 130 (86.1%) 88 (71.5%) 56 (67.5%) — —
Yes 21 (13.9%) 35 (28.5%) 27 (32.5%) 0.001 1.1 0.3, 4.0
Previous diagnosis
No 125 (81.7) 83 (65.9) 76 (90.5) o0.001 — —
Yes 28 (18.3) 43 (34.1) 8 (9.5) 0.6 0.2, 1.4
Cough
No 76 (47.7) 95 (75.4) 76 (90.5) o0.001 — —
Yes 80 (52.3) 31 (24.6) 8 (9.5) 0.9 0.3, 2.9
Chronic expectoration
No 96 (62.7) 92 (73.0) 80 (85.2) o0.001 — —
Yes 57 (37.3) 34 (27.0) 4 (4.8) 7.1 1.2, 41.5
Wheezing
No 41 (26.8) 43 (34.1) 54 (64.3) o0.001 — —
Yes 112 (73.2) 83 (65.9) 30 (35.7) 2.2 0.9, 5.1
Dyspnea
No 123 (80.4) 100 (79.4) 74 (88.1) 0.229 — —
Yes 30 (19.6) 26 (20.6) 10 (11.9) 1.4 0.4, 5.2
Social class
Class I, II 11 (8.3) 9 (7.8) 7 (8.9) — —
Class III 35 (26.3) 37 (31.9) 23 (29.1) 0.910 0.7 0.1, 3.6
Class IV-a, IV-b
and V
87 (65.4) 70 (60.3) 49 (62.0) 0.3 0.1, 1.6
Total SGRQ score, mean (SD)
o7 31 (20.9) 40 (32.3) 47 (58.0) o0.001 — —
7–22 64 (43.2) 36 (29.0) 18 (22.2) 2 0.8, 5.1
422 53 (35.8) 48 (38.7) 16 (19.8) 1.4 0.4, 5.1
Values expressed as n (%), unless otherwise specified. *P-value: unpaired t-test or w2 (Chi-squared), depending on the nature of
the variables.
*OR indicating probability of being a current or former smoker vs. never smoker.
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Table 4 Association between the characteristics of patients and total SGRQ score by multiple linear regression.
B (standard error) Standardized B P-value
Constant 2.3 (3.2) 0.474
Tobacco
Smokers — — —
Former smokers 0.5 (1.6) 0 0.757
Never smokers 1.5 (2.2) 0 0.498
Previous diagnosis
No — — —
Yes 8.0 (1.8) 0.2 0
Age
o55 years — — —
55–64 years 0.6 (1.6) 0 0.736
65 or older 4.0 (1.8) 0.1 0.03
Sex
Female — — —
Male 1.2 (2.2) 0 0.579
Severity of COPD
Very mild (FEV1, % 469) — — —
Mild (FEV1, % 50–69) 2.0 (1.6) 0.1 0.21
Moderate or severe (FEV1, % o50) 5.5 (2.2) 0.1 0.014
Cardiac comorbidity
No — — —
Yes 5.0 (2.3) 0.1 0.03
Cough
No — — —
Yes 7.9 (1.9) 0.2 0
Chronic expectoration
No — — —
Yes 0.0 (2.0) 0 0.989
Wheezing
No — — —
Yes 16.2 (1.9) 0.4 0
Dyspnea
No — — —
Yes 7.6 (1.5) 0.2 0
Social class
Class I, II — — —
Class III 0.2 (2.6) 0 0.937
Class IV-a, IV-b and V 0.2 (2.5) 0 0.93
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A multiple linear regression model was constructed
to investigate which variables were significantly
and independently associated with SGRQ total
scores in this population-based sample of COPD
patients. The model showed that previously diag-
nosed patients had a worse HRQL even after
adjustment for severity based on lung impairmentand respiratory symptoms. These patients pre-
sented a mean of 7.7 (SE ¼ 1.8) units higher (worse)
than patients not previously diagnosed. Among
respiratory symptoms, only chronic expectoration
was not associated with more severe impairment in
HRQL; whereas dyspnea, cough and wheezing were.
Compared with patients with very mild disease,
patients with moderate COPD scored on ave-
rage 6.3 (SE ¼ 2.2) points higher. However, no
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very mild patients. Cardiac comorbidity was sig-
nificantly associated with a worse score and
patients older than 65 years also presented worse
SGRQ scores than the youngest group (Table 4).Discussion
The IBERPOC prevalence study showed that males,
aged over 60 years, with a higher tobacco con-
sumption, symptoms of CB, living in urban areas
and with higher educational levels were signifi-
cantly more likely to have COPD in this population-
based cohort.6 However, only 21.7% of the subjects
identified with COPD had been previously diagnosed
by a physician. In the present study, we have
demonstrated that patients with COPD are more
likely to be diagnosed if they are between 55 and
64 years in age, they present wheezing, have a
previous diagnosis of another chronic respiratory
disease, have a more severe impairment in lung
function and particularly if they have poorer HRQL.
The more severe impairment in lung function
among previously diagnosed patients is not surpris-
ing, since patients with poorer lung function usually
have a longer duration of disease, more frequent
exacerbations19 and, therefore, more clinical visits
with a higher probability of having performed
spirometry. Moreover, impaired HRQL was also
significantly associated with a previous diagnosis
of COPD. It is easy to understand that patients with
poor health status will seek medical attention more
often and will be more likely to undergo diagnostic
tests, including spirometry. In a previous study also
using the ECSC questionnaire, but without spiro-
metric assessment, Huchon et al.20 found a
prevalence of CB of 4.1% (95% CI 3.8–4.5) among
French adults older than 25 years. Diagnosis of CB
was more likely in older individuals and in those
with a comorbidity. Among those without comor-
bidity, only 24% were diagnosed and only 7% were
followed-up. Similarly, in the UK, Renwick and
Connolly8 found that only 55.4% of subjects aged 45
years or over randomly selected from lists of
general practitioners with airway obstruction had
been diagnosed with asthma or CB and only 36.9%
were receiving treatment. The results of the
NHANES III showed that obstructive lung disease
was present in 6.8% of a representative sample of
the US population older than 17 years, but similar
to our results, 63.3% had no prior reported
diagnosis of obstructive lung disease.21 In another
publication from the same survey, Coultas et al.7
showed a prevalence of undiagnosed airflow ob-struction of 12% in the subgroup population of 5743
white participants older than 45 years. It is of note
that over 80% of the participants reported having
seen a physician at least once during the previous
12 months, thereby providing an opportunity for
early detection.7
The present results indicate that there is a very
low degree of suspicion of COPD among physicians,
since only more severe cases in terms of lung
function or HRQL are detected. In favor of this
statement, wheezing was the only symptom sig-
nificantly associated with being previously diag-
nosed on multivariate analysis. This finding suggests
that cough and sputum production in smokers may
be regarded as usual or non-serious for both
physicians and patients. Some studies have demon-
strated the feasibility of screening programs for
COPD, which are less costly than other mass
screening programs.22,23 In Spain, among 3209
individuals older than 35 years with a tobacco
consumption of at least 10 pack-years, 22.5%
showed some degree of airflow obstruction de-
tected in the office of their general practitioner
with a portable spirometer.24
The demonstration of airway obstruction in non-
smokers is a usual finding in epidemiological
studies;22 however, the inclusion of non-smokers
in the definition of COPD is controversial. Older
definitions did not mention tobacco smoking in the
definition of COPD;19,25,26 however, the GOLD
definition includes abnormal inflammatory re-
sponse of the lungs to noxious particles or gases.27
We observed that 23.1% of the COPD cases detected
were never smokers. Considering the total popula-
tion of 4035 individuals, the prevalence of COPD
not related to smoking was 2.1%. The profile of
COPD in never smokers corresponded to women,
with milder impairment in lung function (65.5% had
an FEV1469% predicted) and with fewer respira-
tory symptoms, especially expectoration. Similarly,
the NHANES III showed that 27.5% of women with
undiagnosed airway obstruction were never smo-
kers compared with 10.5% of men.22 In addition, in
Finland, half of the women detected with CB and/
or emphysema in a population-based study had
never been regular smokers compared with only 9%
of men, and women had less severe impairment in
lung function than men.28
Since the current study was not a clinical, but
rather an epidemiological study, no attempt was
made to exclude asthma other than excluding
individuals with a previous diagnosis of asthma or
with a positive BDT. Some of these individuals may
have been diagnosed with asthma if extensive
assessment had been performed. Furthermore,
the increased frequency of other respiratory
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may indicate that the mild chronic airflow obstruc-
tion detected in most cases may be a sequelae of
other respiratory diseases instead of ‘‘real’’ COPD.
In addition, the IBERPOC study was not designed to
investigate the causes of COPD and therefore,
significant exposure to second-hand smoking or
professional exposure to dust of fumes in never
smokers with COPD cannot be ruled out. COPD
among non-smoking women is frequent in some
countries where they are exposed to domestic
biomass fuel combustion when cooking indoors with
poor ventilation,29,30 but this is not a risk factor in
Spain.
The interest of our findings lies in the character-
ization of COPD in never smokers in the community.
These individuals were detected in a random
sample of the general population. Previous studies
of COPD in non-smokers were based on patients in
whom the disease was severe enough for them to
seek medical attention and represent more ad-
vanced stages of the disease. In a previous study,
Birring et al.31 identified only 5.7% of the total
referrals to their center for COPD as being non-
smokers. This is much lower than the 23.1% of non-
smokers among our population of COPD detected in
the community and suggests that non-smokers may
have a milder course of the disease, most remain-
ing as milder cases and not being diagnosed. In
fact, only 9.5% of never smokers had been
diagnosed with COPD in our study compared with
25.4% of smokers or former smokers (P ¼ 0:002).
This is also suggested in the former study with the
observation of a mean FEV1 (%) of 58% despite an
advanced mean age of 70 years in women with
COPD.31 The authors also consistently found that
86% of the non-smoking COPD patients were women
and no significant passive smoking or professional
exposure to pollutants were identified. Their
findings suggested a role for eosinophilic inflamma-
tion and/or organ-specific autoimmunity as patho-
genic mechanisms in this population.31 The higher
percentage of former smokers with a previous
diagnosis compared with both, smokers and never
smokers, in our opinion does not mean that
physicians are more likely to diagnose those who
gave up smoking, but it may reflect that patients
are more motivated to give up smoking after the
diagnosis of COPD.
The results of the IBERPOC study allowed
reference values to be established for the SGRQ
in the Spanish population from 40 to 69 years of
age.32 All the subgroups of patients identified
scored worse than the general population. Pre-
viously diagnosed patients presented the worst
total SGRQ score (31.9; SD ¼ 20.2), and the sub-group of never smokers had the best score (11.9;
SD ¼ 16.6). When analyzing the factors associated
with the SGRQ score in this population-based
sample, all respiratory symptoms except expectora-
tion were strongly associated with impairment in
HRQL. Interestingly enough, impairment in HRQL
measured by the total SGRQ score, has been shown
to be significantly associated with the previous
diagnosis of COPD. This is a new finding that
highlights the importance of health status in chronic
lung disease. It has been demonstrated that HRQL is
related to hospital admission,33 re-admission 34 and
mortality35 in patients with COPD. In addition, HRQL
has shown to be a valuable tool in the evaluation of
the therapeutic effect of drugs36 and their interac-
tions.37 Our results show that health status also
contributes to the likelihood of early diagnosis and
reinforce the current view that COPD should be
classified and managed while taking various aspects
of the disease beyond the lung function impairment
into account.38 Among these aspects, specific HRQL
questionnaires should play a pivotal role, particu-
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